Novartis Settles Patent Litigation Over Gleevec - - BioPharm International

ADVERTISEMENT

Novartis Settles Patent Litigation Over Gleevec



Novartis Pharmaceuticals has settled its litigation with the US subsidiary of Sun Pharmaceutical Industries, regarding patents covering the use of certain polymorphic forms of Gleevec (imatinib mesylate), which expire in 2019 (including pediatric exclusivity). The basic compound patent for Gleevec expires in the US on July 4, 2015.

As a result of the settlement, Novartis will permit Sun Pharma's subsidiary to market a generic version of Gleevec in the US on February 1, 2016. The terms of the settlement agreement are otherwise confidential. Sun Pharma's subsidiary has received tentative approval from FDA for its generic version of imatinib mesylate.

Source: Novartis Pharmaceuticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines

Click here